“Now as more implanters complete their training, we expect EV-ICD sales to ramp and become a significant driver of CRM growth, taking share from the competitor's S-ICD system.”

In context

“dtronic to expand our business. Next, in Cardiac Rhythm Management, Cardiac Pacing Therapies delivered another strong quarter of high-single-digit growth. Our Micra leadless pacemaker franchise grew over 20%, driven by the adoption of our latest generation, Micra AV2 and VR2, which improved procedure efficiency and increased battery longevity by 40% to 16 or 17 years. Now we hold the vast majority of share in the leadless pacing space. We also continue to expand our pacing leadership as the only company to offer an approved lead for an innovative alternative form of pacing called Conduction System Pacing. Our 3830 conduction system pacing lead grew over 40%. In Defibrillation Solutions, we're seeing good early adoption of our innovative Aurora EV-ICD, which requires no leads in the heart. Now as more implanters complete their training, we expect EV-ICD sales to ramp and become a significant driver of CRM growth, taking share from the competitor's S-ICD system. Next, in Surgical, we grew 5%. Our Advanced Energy product lines grew high-single-digits on the continued launch of our Ligasure XP Maryland vessel sealer. We've now taken energy share from our main competitor for six quarters in a row. Our Wound Management business also grew high-single-digits as strong sales of our V-Loc barbed sutures also resulted in continued share gains from our main competitor. In Q4, we expanded the capabilities of our Touch Surgery digital ecosystem. Just as our AiBLE ecosystem is transforming Spine, Touch Surgery is transforming laparoscopic and robotic surgical procedures. We collect robust datasets from surgeries, including video, to create models that inject intelligence into these procedures. We've launched 14 new AI-based algorithms on our Touch Surgery Per”